30 November 2022 - Article
Represented Medovate Limited, a vehicle established to enable the commercialisation of intellectual property generated from NHS Trusts in East Anglia.
Company counsel for a number of drug discovery companies based in Cambridge who are backed by venture capital investors and advises them in respect of their funding rounds, day to day general corporate and restructuring requirements.
Involved in the commercialisation of technology from research institutions such as the University of Cambridge and Imperial Innovations representing founders and the spin out companies as well as investors in this process.
Company counsel for high growth technology companies advising them from formation to seed funding through to institutional investment.
Advises several accelerators providing programmes and early stage investment to start-up companies and have prepared their template documents for these investments and provides support to these programmes.
Advises institutional investors in respect of seed and Series A+ fundings of high growth companies in multiple jurisdictions.
England and Wales, 1999
Co-author of the BVCA model documents and drafting notes
BVCA working committee
Key participant of the 2015 industry review of the BVCA model documents and was responsible for the drafting these revised BVCA model document
Provided several presentations about key issues facing early stage companies seeking venture capital investment.
InsightView all Firm insight
30 November 2022 - Firm News
Withers tech advises as Edenred Capital Partners joins a £5 million seed investment into 5Mins AI
29 November 2022 - Events
The onset of the CISG in Hong Kong and recent developments in international trade law worldwide
24 November 2022 - Article
How can UK or US courts protect your business from a ransomware or cyber-attack?
23 November 2022 - In The Press
Court of Justice of the European Union rules anti-money laundering directive provision invalid
22 November 2022 - Article